Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Results of taxane class drug study in early stage breast cancer published
June 30th, 2005
The sanofi-aventis group announced that the New England Journal of Medicine has published the results of a phase 3 study of adjuvant (after surgery) Taxotere (docetaxel) Injection Concentrate. The study demonstrates that an adjuvant (after surgery) Taxotere (docetaxel) Injection Concentrate-based regimen showed a significant 28% reduction in risk of relapse (p=0.001) and a significant 30% reduction in the risk of death (p=0.008) after 55 months of follow-up in women with operable, node-positive breast cancer. The results were observed regardless of the nodal, hormone-receptor, menopausal and HER-2/neu status. Conducted by the Breast Cancer...
Source: Women's Health Weekly (2005-06-30)
|
